

October 26, 2006

Contact Information:
Corporate Communications
Astellas Pharma Inc.
TEL: +81-3-3244-3201

Revision of the Interim Business Forecasts for FY2006

Astellas Pharma Inc. (hereinafter referred as “the Company”) today announced that it decided at the meeting of Board of Directors to revise as follows the consolidated and non-consolidated business forecasts for the first half of FY2006 (from April 1, 2006 to September 30, 2006) which were announced on May 15, 2006. The full year business forecasts of the Company remain unchanged at this time.

- Revised consolidated and non-consolidated business forecasts for the 1st half of FY2006 (April 1, 2006 - September 30, 2006)

(million yen)

		Net Sales	Operating Income	Ordinary Income	Net Income
Initial forecasts on May 15, 2006 (A)	Non-consolidated	289,000	28,000	30,000	33,000
	Consolidated	438,000	68,000	70,000	54,000
Revised forecasts (B)	Non-consolidated	295,900	39,600	43,500	46,200
	Consolidated	447,900	72,400	77,000	60,600
Changes (B)-(A)	Non-consolidated	+6,900	+11,600	+13,500	+13,200
	Consolidated	+9,900	+4,400	+7,000	+6,600
Percentage of changes (%)	Non-consolidated	+2.4%	+41.4%	+45.0%	+40.0%
	Consolidated	+2.3%	+6.5%	+10.0%	+12.2%

Reasons of the revisions

Consolidated net sales are expected to increase over the initial forecasts thanks to sales increases in Japan, North America, Europe and Asia. Profits at each stage also are expected to increase over the initial forecasts due to research and development expenses lowered than the initial forecasts because of efficient use of expenses and delay of some payments while the cost of sales ratio is expected to go up from the initial forecasts.

Non-consolidated sales and profits at each stage are expected to increase over the initial forecasts thanks to rise in export sales including export to overseas subsidiaries over the initial forecasts as well as research and development expenses lowered than the initial forecasts by the same reason described above.

Positive impacts by yen's depreciation against US \$ and euro are included in increases in both sales and profits above mentioned.

<Reference information>

Business results for the 1st half of FY2005 (April 1, 2005 – September 30, 2005)

(million yen)

	Net Sales	Operating Income	Ordinary Income	Net Income
Non-consolidated	287,450	80,811	81,336	51,923
Consolidated	426,723	117,147	122,017	67,317

Note:

The foregoing are forward-looking statements based on a number of assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties. Actual financial results may differ materially depending on a number of factors including, adverse economic conditions, currency exchange rate fluctuations, adverse legislative and regulatory developments, delays in new product launches, pricing and product initiatives of competitors, the inability of the Company or its subsidiaries or affiliates to market existing and new products effectively, interruptions in production, infringements of the intellectual property rights of the Company or its subsidiaries or affiliates and the adverse outcome of material litigation.

- # # # -